The role of immunity in Huntington's disease

Molecular Psychiatry

Volumn 16, Issue 9, 2011, Pages 889-902

  Soulet, D ^a,b   Cicchetti, F ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Anti inflammatory treatment; immune response; inflammation; mutant huntingtin; neurodegenerative diseases

Indexed keywords

3 NITROPROPIONIC ACID; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CYCLOHEXIMIDE; DEXAMETHASONE; DOXYCYCLINE; HUNTINGTIN; MINOCYCLINE; PLACEBO; POLYGLUTAMINE; REMACEMIDE; ROFECOXIB;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG EFFICACY; DRUG WITHDRAWAL; EXPERIMENTAL ANIMAL; HUMAN; HUNTINGTON CHOREA; HYPERPIGMENTATION; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SPINAL CORD INJURY; STROKE; TOXICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; HUNTINGTON DISEASE; IMMUNE SYSTEM DISEASES; IMMUNITY; INFLAMMATION; MODELS, IMMUNOLOGICAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

EID: 80052074316     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.28     Document Type: Review

References (81)

1. Van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009; 8: 765-774.
2. Wright BL, Barker RA. Established and emerging therapies for Huntington0s disease. Curr Mol Med 2007; 7: 579-587. (Pubitemid 47618054)
3. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington0s disease. Mov Disord 2008; 23: 1491-1504.
4. Frank S, Jankovic J. Advances in the pharmacological management of Huntington0s disease. Drugs 2010; 70: 561-571.
5. Gil JM, Rego AC. Mechanisms of neurodegeneration in Huntington0s disease. Eur J Neurosci 2008; 27: 2803-2820.
6. Borrell-Pages M, Zala D, Humbert S, Saudou F. Huntington0s disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006; 63: 2642-2660. (Pubitemid 44800717)
7. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003; 23: 137-149. (Pubitemid 36188452)
8. Soulet D, Rivest S. Microglia. Curr Biol 2008; 18: R506-R508.
9. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310: 1510-1512. (Pubitemid 41746349)
10. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577. (Pubitemid 16196286)
11. Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60: 161-172. (Pubitemid 32172419)
12. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72: 148-151. (Pubitemid 46389550)
13. Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington0s disease: a multimodal imaging study. Hum Brain Mapp 2011; 32: 258-270.
14. Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2010; 37: 356-361.
15. Moller T. Neuroinflammation in Huntington's disease. J Neural Transm 2010; 117: 1001-1008.
16. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008; 205: 1869-1877.
17. Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C et al. Neuroendocrine disturbances in Huntington's disease. PLoS One 2009; 4: e4962.
18. Mukai H, Isagawa T, Goyama E, Tanaka S, Bence NF, Tamura A et al. Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 10887-10892. (Pubitemid 41105962)
19. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA et al. Quantitative neuropathological changes in presymptomatic Huntington0s disease. Ann Neurol 2001; 49: 29-34. (Pubitemid 32163003)
20. Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813-822. (Pubitemid 29189048)
21. Moffitt H, McPhail GD,Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009; 4: e8025.
22. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106: 22480-22485.
23. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171: 1001-1012.
24. Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L et al. Impaired glutamate uptake in the R6 Huntington0s disease transgenic mice. Neurobiol Dis 2001; 8: 807-821. (Pubitemid 33055597)
25. Behrens PF, Franz P,Woodman B, Lindenberg KS, Landwehrmeyer GB. Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002; 125: 1908-1922.
26. Hsiao HY, Chern Y. Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol 2010; 41: 248-255.
27. Hassel B, Tessler S, Faull RL, Emson PC. Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008; 33: 232-237.
28. Cicchetti F, Soulet D, Freeman TB. Neuronal degeneratin in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2010; 34: 641-652.
29. Arzberger T, Krampfl K, Leimgruber S, Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington0s disease-an in situ hybridization study. J Neuropathol Exp Neurol 1997; 56: 440-454. (Pubitemid 27465027)
30. Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH et al. Expandedpolyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 2008; 28: 3277-3290. (Pubitemid 351469331)
31. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000; 21: 141-147.
32. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 2005; 81: 302-313. (Pubitemid 41359284)
33. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166: 7527-7533. (Pubitemid 32525632)
34. Wang X, Zhu S, Drodza M, Zhang W, Stavrovskaya IG, Cattaneo E et al. Minocycline inhibits caspase-independent and-dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 10483-10487. (Pubitemid 37071904)
35. Wang X, Chen S, Ma G, Ye M, Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2\+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 2005; 126: 1241-1254. (Pubitemid 41572241)
36. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington0s disease excitotoxicity. Brain 2009; 132: 3152-3164.
37. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285: 10653-10661.
38. Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679. (Pubitemid 41051778)
39. Singhrao SK, Neal JW, Morgan BP, Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999; 159: 362-376. (Pubitemid 29485223)
40. Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkappaB kinase complex and nuclear factorkappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24: 7999-8008. (Pubitemid 39280819)
41. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70: 1916-1925. (Pubitemid 351684646)
42. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson0s disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
43. Haik S, Faucheux BA, Hauw JJ. Brain targeting through the autonomous nervous system: lessons from prion diseases. Trends Mol Med 2004; 10: 107-112.
44. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614. (Pubitemid 350076090)
45. Roodveldt C, Christodoulou J, Dobson CM. Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 2008; 12: 1820-1829.
46. Morten IJ, Gosal WS, Radford SE, Hewitt EW. Investigation into the role of macrophages in the formation and degradation of beta2-microglobulin amyloid fibrils. J Biol Chem2007; 282: 29691-29700. (Pubitemid 350043347)
47. Yang W, Dunlap JR, Andrews RB, Wetzel R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002; 11: 2905-2917.
48. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 219-225.
49. Qureshi N, Vogel SN, Van Way C III, Papasian CJ, Qureshi AA, Morrison DC. The proteasome: a central regulator of inflammation and macrophage function. Immunol Res 2005; 31: 243-260. (Pubitemid 40628961)
50. Tydlacka S, Wang CE, Wang X, Li S, Li XJ. Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008; 28: 13285-13295.
51. Barres BA, Barde Y. Neuronal and glial cell biology. Curr Opin Neurobiol 2000; 10: 642-648.
52. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002; 22: 1592-1599. (Pubitemid 35386278)
53. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797-801. (Pubitemid 30469429)
54. Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 54: 186-196. (Pubitemid 36909617)
55. Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C et al. Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med 2007; 9: 47-54. (Pubitemid 44772275)
56. Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW et al. Combination therapy using minocycline and coenzyme Q10 in R6/2. transgenic Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 373-380. (Pubitemid 43172854)
57. Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M et al. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 2004; 17: 319-325. (Pubitemid 39345787)
58. Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 2005; 18: 206-217. (Pubitemid 40092910)
59. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006; 141: 1835-1848. (Pubitemid 44233147)
60. Menalled LB, Patry M, Ragland N, Lowden PA, Goodman J, Minnich J et al. Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010; 5: e9793.
61. Bonelli RM, Heuberger C, Reisecker F. Minocycline for Huntington's disease: an open label study. Neurology 2003; 60: 883-884. (Pubitemid 36297384)
62. Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19: 337-342. (Pubitemid 39506988)
63. Thomas M, Ashizawa T, Jankovic J. Minocycline in Huntington's disease: a pilot study. Mov Disord 2004; 19: 692-695. (Pubitemid 39173025)
64. Reynolds N. Revisiting safety of minocycline as neuroprotection in Huntington's disease. Mov Disord 2007; 22: 292. (Pubitemid 46374790)
65. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168-179.
66. Giuliani F, Hader W, Yong VW. Minocycline attenuates T cell and microglia activity to impair cytokine production in T cellmicroglia interaction. J Leukoc Biol 2005; 78: 135-143. (Pubitemid 40979952)
67. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport 2004; 15: 2181-2184. (Pubitemid 39392235)
68. Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004; 186: 248-251. (Pubitemid 38333198)
69. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 337-343. (Pubitemid 36638766)
70. Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, Skepper JN et al. Paradoxical delay in the onset of disease caused by superlong CAG repeat expansions in R6/2 mice. Neurobiol Dis 2009; 33: 331-341.
71. Dragatsis I, Goldowitz D, Del Mar N, Deng YP, Meade CA, Liu L et al. CAG repeat lengths 〉 or = 335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiol Dis 2009; 33: 315-330.
72. Menalled LB, Chesselet MF. Mouse models of Huntington's disease. Trends Pharmacol Sci 2002; 23: 32-39. (Pubitemid 34135973)
73. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65: 267-277. (Pubitemid 38443548)
74. Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington0s disease age of onset. Proc Natl Acad Sci USA 2004; 101: 3498-3503. (Pubitemid 38338224)
75. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993; 4: 387-392. (Pubitemid 23231488)
76. Nuti A, Maremmani C, Ceravolo R, Pavese N, Bonuccelli U, Muratorio A. Dexamethasone therapy in Huntington chorea: preliminary results. Riv Neurol 1991; 61: 225-227.
77. Bonucelli U, Nuti A, Maremmani C, Ceravolo R, Muratorio A. Steroid therapy in Huntington's disease. In: Biggio G, Concas A, Costa E (ed). Advances in Biochemical Psychopharmacology. Rave Press: New York, USA, 1992, pp 149-154.
78. Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A. Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 2009; 219: 385-397.
79. Soulet D, Rivest S. Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol 2008; 8: 508-518.
80. Bjorkqvist M, Wild EJ, Tabrizi SJ. Harnessing immune alterations in neurodegenerative diseases. Neuron 2009; 64: 21-24.
81. Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759-1766. (Pubitemid 47343790)